- The FDA approves the expanded use of Roche's (OTCQX:RHHBY) hepatitis C virus (HCV) quantitative RNA test that is used as an aid in the diagnosis of HCV infection in certain patients. The test, the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0, can now be used to confirm active hepatitis infection in addition to providing an accurate measurement of how much virus is present in a patient's blood.
- The confirmatory labeling means that no additional test needs to be performed to confirm the presence of an active HCV infection, thereby saving time and money.
- Roche's test was the first quantitative HCV RNA test approved for use as an aid in the diagnosis of active HCV infection.